Gilead Sciences annual shareholders’ equity
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gilead Sciences Shareholders’ Equity Growth & History (GILD)
Gilead Sciences's shareholders’ equity was $22.70B for fiscal 2025.
View full Gilead Sciences company overviewGilead Sciences annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $22.70B | $3.37B | +17.45% |
| 2024 | 2024-12-31 | $19.33B | −$3.50B | −15.34% |
| 2023 | 2023-12-31 | $22.83B | $1.59B | +7.50% |
| 2022 | 2022-12-31 | $21.24B | $171.0M | +0.81% |
| 2021 | 2021-12-31 | $21.07B | $2.87B | +15.75% |
| 2020 | 2020-12-31 | $18.20B | −$4.32B | −19.19% |
| 2019 | 2019-12-31 | $22.52B | $1.14B | +5.32% |
| 2018 | 2018-12-31 | $21.39B | $945.0M | +4.62% |
| 2017 | 2017-12-31 | $20.44B | $1.55B | +8.23% |
| 2016 | 2016-12-31 | $18.89B | $353.0M | +1.90% |
| 2015 | 2015-12-31 | $18.53B | $3.11B | +20.15% |
| 2014 | 2014-12-31 | $15.43B | $4.06B | +35.67% |
| 2013 | 2013-12-31 | $11.37B | $2.07B | +22.22% |
| 2012 | 2012-12-31 | $9.30B | $2.56B | +38.04% |
| 2011 | 2011-12-31 | $6.74B | $875.1M | +14.92% |
| 2010 | 2010-12-31 | $5.86B | −$503.3M | −7.91% |
| 2009 | 2009-12-31 | $6.37B | $2.09B | +49.02% |
| 2008 | 2008-12-31 | $4.27B | $519.9M | +13.86% |
| 2007 | 2007-12-31 | $3.75B | — | — |
Gilead Sciences quarterly shareholders’ equity
Q4.08
Q2.09
Q3.09
Q4.09
Q1.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $11.83B | −$7.84B | −39.87% |
| Q1 2026 | 2026-03-31 | $23.52B | $4.35B | +22.72% |
| Q4 2025 | 2025-12-31 | $22.70B | $3.37B | +17.45% |
| Q3 2025 | 2025-09-30 | $21.54B | $3.06B | +16.59% |
| Q2 2025 | 2025-06-30 | $19.67B | $1.39B | +7.62% |
| Q1 2025 | 2025-03-31 | $19.16B | $1.62B | +9.25% |
| Q4 2024 | 2024-12-31 | $19.33B | −$3.50B | −15.34% |
| Q3 2024 | 2024-09-30 | $18.48B | −$3.84B | −17.20% |
| Q2 2024 | 2024-06-30 | $18.28B | −$2.88B | −13.60% |
| Q1 2024 | 2024-03-31 | $17.54B | −$3.46B | −16.47% |
| Q4 2023 | 2023-12-31 | $22.83B | $1.59B | +7.50% |
| Q3 2023 | 2023-09-30 | $22.31B | $1.23B | +5.85% |
| Q2 2023 | 2023-06-30 | $21.16B | $922.0M | +4.56% |
| Q1 2023 | 2023-03-31 | $21.00B | $1.07B | +5.37% |
| Q4 2022 | 2022-12-31 | $21.24B | $171.0M | +0.81% |
| Q3 2022 | 2022-09-30 | $21.08B | −$389.0M | −1.81% |
| Q2 2022 | 2022-06-30 | $20.24B | $533.0M | +2.71% |
| Q1 2022 | 2022-03-31 | $19.93B | $975.0M | +5.14% |
| Q4 2021 | 2021-12-31 | $21.07B | $2.87B | +15.75% |
| Q3 2021 | 2021-09-30 | $21.47B | $4.03B | +23.07% |
| Q2 2021 | 2021-06-30 | $19.70B | $1.68B | +9.30% |
| Q1 2021 | 2021-03-31 | $18.95B | −$3.12B | −14.12% |
| Q4 2020 | 2020-12-31 | $18.20B | −$4.32B | −19.19% |
| Q3 2020 | 2020-09-30 | $17.45B | −$3.16B | −15.33% |
| Q2 2020 | 2020-06-30 | $18.03B | −$4.59B | −20.29% |
| Q1 2020 | 2020-03-31 | $22.07B | $116.0M | +0.53% |
| Q4 2019 | 2019-12-31 | $22.52B | $1.14B | +5.32% |
| Q3 2019 | 2019-09-30 | $20.60B | −$2.26B | −9.87% |
| Q2 2019 | 2019-06-30 | $22.62B | $944.0M | +4.36% |
| Q1 2019 | 2019-03-31 | $21.95B | $1.36B | +6.60% |
| Q4 2018 | 2018-12-31 | $21.39B | $945.0M | +4.62% |
| Q3 2018 | 2018-09-30 | $22.86B | −$1.98B | −7.99% |
| Q2 2018 | 2018-06-30 | $21.67B | −$1.00B | −4.43% |
| Q1 2018 | 2018-03-31 | $20.59B | $150.0M | +0.73% |
| Q4 2017 | 2017-12-31 | $20.44B | $1.55B | +8.23% |
| Q3 2017 | 2017-09-30 | $24.84B | $7.98B | +47.29% |
| Q2 2017 | 2017-06-30 | $22.68B | $7.14B | +45.96% |
| Q1 2017 | 2017-03-31 | $20.44B | $7.04B | +52.57% |
| Q4 2016 | 2016-12-31 | $18.89B | $353.0M | +1.90% |
| Q3 2016 | 2016-09-30 | $16.87B | −$546.0M | −3.14% |
| Q2 2016 | 2016-06-30 | $15.54B | −$751.0M | −4.61% |
| Q1 2016 | 2016-03-31 | $13.40B | −$3.78B | −22.01% |
| Q4 2015 | 2015-12-31 | $18.53B | $3.11B | +20.15% |
| Q3 2015 | 2015-09-30 | $17.41B | $3.85B | +28.36% |
| Q2 2015 | 2015-06-30 | $16.29B | $196.4M | +1.22% |
| Q1 2015 | 2015-03-31 | $17.18B | $3.79B | +28.33% |
| Q4 2014 | 2014-12-31 | $15.43B | $4.06B | +35.67% |
| Q3 2014 | 2014-09-30 | $13.57B | $2.68B | +24.65% |
| Q2 2014 | 2014-06-30 | $16.09B | $5.00B | +45.07% |
| Q1 2014 | 2014-03-31 | $13.39B | $3.24B | +31.87% |
| Q4 2013 | 2013-12-31 | $11.37B | $2.07B | +22.22% |
| Q3 2013 | 2013-09-30 | $10.88B | $2.28B | +26.50% |
| Q2 2013 | 2013-06-30 | $11.09B | $3.09B | +38.61% |
| Q1 2013 | 2013-03-31 | $10.15B | $2.84B | +38.81% |
| Q4 2012 | 2012-12-31 | $9.30B | $2.56B | +38.04% |
| Q3 2012 | 2012-09-30 | $8.60B | $2.49B | +40.66% |
| Q2 2012 | 2012-06-30 | $8.00B | $1.96B | +32.34% |
| Q1 2012 | 2012-03-31 | $7.31B | $1.37B | +23.00% |
| Q4 2011 | 2011-12-31 | $6.74B | $875.1M | +14.92% |
| Q3 2011 | 2011-09-30 | $6.12B | $410.4M | +7.19% |
| Q2 2011 | 2011-06-30 | $6.05B | — | — |
| Q1 2011 | 2011-03-31 | $5.95B | −$1.40B | −19.01% |
| Q4 2010 | 2010-12-31 | $5.86B | −$503.3M | −7.91% |
| Q3 2010 | 2010-09-30 | $5.71B | $59.8M | +1.06% |
| Q1 2010 | 2010-03-31 | $7.34B | — | — |
| Q4 2009 | 2009-12-31 | $6.37B | $2.09B | +49.02% |
| Q3 2009 | 2009-09-30 | $5.65B | — | — |
| Q2 2009 | 2009-06-30 | $5.19B | — | — |
| Q4 2008 | 2008-12-31 | $4.27B | — | — |
Gilead Sciences shareholders’ equity trends
Over the last five fiscal years, Gilead Sciences's shareholders’ equity increased from $18.20B to $22.70B, a change of $4.50B. The latest reported quarter, Q2 2026, shows $11.83B.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gilead Sciences source filings ↗Community posts
Gilead raises its sales outlook but projects a deeper acquisition-driven annual loss
Gilead ($GILD) increased its 2026 product-sales forecast to $31.0–$31.3 billion from $30.1–$30.4 billion after third-quarter 2026 product revenue rose 13% to $8.3 billion. HIV sales grew 18% to $6.2 billion, supported by demand, pricing and ...
Gilead agrees $1.275 billion purchase of PepStar's oral inflammation program
Gilead ($GILD) agreed to acquire worldwide rights to PepStar's investigational oral IL-23 receptor inhibitor program, led by HCXT-2001. The agreement calls for $1.275 billion in upfront cash consideration payable at closing, subject to cust ...
